“There is an increasing need to find stronger immunogens that can be used to create more effective vaccines. One promising candidate is α-galactosyl immunogens, which have shown great potential in animals, but we don’t know much about if and how they would work in humans,” said Singh. “We are excited that the IBB seed grant will allow us to combine the Singh lab’s expertise in creating human immune tissues in the lab with the Finn lab’s unique skills in designing these immunogens. This collaboration will help us better understand how these potential vaccine ingredients perform in human-like systems.”
https://research.gatech.edu/ibb-announces-fy25-seed-grant-recipients
